Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Airbus Spain Workers Approve Deal to End Months of Strikes 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Disney Plans TV Restructuring With Hundreds of Layoffs 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
WordPress Malware Uses Ethereum to Evade Removal 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Add as a preferred source on Google
OXFORD, United Kingdom, March 27, 2017 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2017 on Wednesday, 29 March 2017.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the full year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics | |||
| Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: | +44 (0)1235 443 951 +1 617 225 4455 | |
| Cairn Financial Advisers LLP | |||
| (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: | +44 (0)20 7213 0880 | |
| N+1 Singer | |||
| (Broker) Aubrey Powell / Jen Boorer | Tel: | +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications | |||
| (US media contact) | Tel: | +1 781 235 3060 | |
| Chris Erdman / Karen Sharma | [email protected] [email protected] | ||
| Consilium Strategic Communications | |||
| (Financial public relations, UK) | Tel: | +44 (0)20 3709 5700 | |
| Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | [email protected] | ||
-END-
